

NCIC CLINICAL TRIALS GROUP
MYELOMA SUBCOMMITTEE AGENDA
DELTA CHELSEA HOTEL, TORONTO, ON
SATURDAY, APRIL 27TH, 2013—3:30-4:15 PM

- | | | |
|-----------|--|-----------|
| 3:30-3:35 | Welcome, objectives and agenda | D. Reece |
| 3:35-3:50 | Maintenance therapy after ASCT | D. Reece |
| | <ul style="list-style-type: none">- Update of ECOG 100104 trial of lenalidomide versus placebo after ASCT- Proposal: SWOG Phase III study of lenalidomide versus lenalidomide + ixazomib as maintenance therapy post-ASCT in patients with multiple myeloma | |
| 3:50-4:10 | PARP inhibition with bortezomib in relapsed myeloma | N. Bahlis |
| 4:10-4:15 | Potential new agent(s) for phase II stud | S. Trudel |
| | <ul style="list-style-type: none">- Cabozantinib (Exelixis), small molecule inhibitor of tyrosine kinases | |